Gujarat Themis Biosyn Limited Stock

Equities

GUJTHEM6

INE942C01045

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:50 2024-05-13 am EDT 5-day change 1st Jan Change
402.3 INR +0.95% Intraday chart for Gujarat Themis Biosyn Limited -0.64% +56.81%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2022 1.15B 13.76M Sales 2023 1.49B 17.85M Capitalization 9.97B 119M
Net income 2022 436M 5.22M Net income 2023 580M 6.95M EV / Sales 2022 4.97 x
Net cash position 2022 209M 2.5M Net cash position 2023 84.84M 1.02M EV / Sales 2023 6.64 x
P/E ratio 2022
13.6 x
P/E ratio 2023
17.2 x
Employees 109
Yield 2022
1.47%
Yield 2023
0.79%
Free-Float 27.98%
More Fundamentals * Assessed data
Dynamic Chart
Gujarat Themis Biosyn Limited Approves an Interim Dividend for the Year 2023-24 CI
Gujarat Themis Biosyn Limited Approves Interim Dividend for the Financial Year 2023-24 CI
Gujarat Themis Biosyn Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Gujarat Themis Biosyn Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Gujarat Themis Biosyn Limited Recommends Dividend for Financial Year Ended March 31, 2023 CI
Gujarat Themis Biosyn Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Gujarat Themis Biosyn Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Gujarat Themis Biosyn Names New CEO MT
Gujarat Themis Biosyn Limited Appoints Tapas Guha Thakurata as Chief Executive Officer CI
Gujarat Themis Biosyn Board Declares Interim Dividend for Fiscal 2023 MT
Gujarat Themis Biosyn Limited Approves Declaration of an Interim Dividend for the Financial Year 2022-23 CI
Gulf Oil Lubricants' Net Profit Slides in Fiscal Q2 MT
Gujarat Themis Biosyn's Net Profit Climbs in Fiscal Q2 MT
Gujarat Themis Biosyn Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Themis Medicare Limited entered into share purchase agreement to acquire additional 6.47% stake in Gujarat Themis Biosyn Limited from Pharmaceutical Business Group Limited for approximately INR 700 million. CI
More news
1 day+0.95%
1 week-0.64%
Current month-2.01%
1 month+4.51%
3 months+21.01%
6 months+119.42%
Current year+56.81%
More quotes
1 week
391.15
Extreme 391.15
430.00
1 month
367.85
Extreme 367.85
435.00
Current year
267.00
Extreme 267
435.00
1 year
145.80
Extreme 145.8
435.00
3 years
50.00
Extreme 50
435.00
5 years
6.28
Extreme 6.28
435.00
10 years
1.80
Extreme 1.8
435.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 14-08-06
Director of Finance/CFO - -
Compliance Officer - 21-05-11
Members of the board TitleAgeSince
Director/Board Member 66 06-03-30
Director/Board Member 49 08-10-24
Chairman 75 92-05-24
More insiders
Date Price Change Volume
24-05-13 402.3 +0.95% 42 755
24-05-10 398.5 +0.61% 31,969
24-05-09 396.1 -3.28% 45,661
24-05-08 409.6 -1.53% 76,326
24-05-07 415.9 -1.69% 52,449

Delayed Quote Bombay S.E., May 13, 2024 at 06:00 am EDT

More quotes
Gujarat Themis Biosyn Limited is an India-based company, which is principally engaged in the manufacturing of pharmaceuticals and medicinal chemical products. The Company is focused on the business of manufacturing and sale of finished active pharmaceutical ingredients (API) products by fermentation process. The Company operates through manufacturing of the bulk drugs segment. Its product portfolio comprises Rifamycin-O and Rifamycin-S. The Company is manufacturing Rifamycin S, which is an intermediate for manufacturing the drug Rifampicin (an Antibiotic used for the treatment of several types of bacterial infections, including tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease.) and Rifamycin O, which is an intermediate for manufacturing the drug Rifaximin (this is an Antibiotic used for treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy). Its research and development division focuses on developing fermentation cultures.
More about the company
  1. Stock Market
  2. Equities
  3. GUJTHEM6 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW